The main result was the reduction in primary and nodal volumes due to better definition of lung mass and nearby lung Collapse , the latter could be easily defined in 14 cases on the DW-MRI vs. 7 cases only by CT scans (P=0.016). Median GTV total (sum of 1ry and nodal GTV), on MRI Diffusion compared to that on the CT scan was 354 and 386 cm3 respectively (P= 0.009). In 15 cases, a mean decrease in the GTV total of 34% ±56% (median, 9%; range, 0.2-32.5%) by using DW-MRI. only in three other cases a mean increase in the GTV total of 12.7% ±14.9% (median, 9.7%; range, 0.4-221%). was found. The median PTVs on the CT scans vs. the MRI Diffusion were 1623 (range, 493-2965 cm3) & 1419 (range, 542-3158 cm3) respectively which was statistically non significant (P= 0.391).
Russian Scientific Center of Roentgenoradiology, Surgery, Moscow, Russian Federation 3 Russian Scientific Center of Roentgenoradiology, Scientific, Moscow, Russian Federation Purpose or Objective: Purpose: The aim of this work was to compare the patterns of NSCLC relapses after combined modality therapy with postoperative hypofractionated and conventionally fractionated radiotherapy and after sugery Material and Methods: Material/methods. We treated 528 patients between January 1990 and January 2014 (men -445, women -83) aged 27-78 years (median age 59) with morphologically proven NSCLC (adenocarcinoma -161, squamous cell cancer-289, other types -70 patients); stage I-126, stage II -117, III -111. All patients were operated: pnevmonectomy -180, lobe/belobectomy -304, segmentectomy -30, wedge resection -11. 227 patients received neoadjuvant or adjuvant platinum-based chemotherapy. Three groups were retrospectively analyzed: group I -174 patients without postoperative radiotherapy (PORT), group II -180 patients with postoperative hypofractionated radiotherapy with daily dose 3Gy up to the total dose 36Gy-39Gy (EQD2= 43-47Gy, α/β=3) and group III -174 patients with postoperative radiotherapy with daily dose 2Gy up to the total dose 44Gy. Bronchial stump, involved regional lymphatic nodes and uninvolved groups (2R, 2L, 3a, 3p, 4R, 4L, 5, 6, 7 according to IASLC classification) were included in the CTV. The groups were comparable in the following parameters: age, ECOG status, stage, T-and Nclassification and the proportion of the patients treated with chemotherapy. The duration of the follow-up was 0,33-16,0 years, median -2,25 years. The relapses were classified as local (in bronchial stump), regional, or distant. In the cases of mixt relapses (local ± regional ±distant) they were included in each category.
Results:
Results. 263(49,8%) patients relapsed: 231 (43,8%) had distant metastases, local relapse -51 (9,7%), regional relapse -54 (10,2%). The pattern of the relapses in each group is presented in the table.
Conclusion:
Conclusion. Hypofractionated postoperative radiotherapy (daily dose 3Gy, total dose 36-39Gy) significantly decrease the probability of local and regional relapse in NSCLC patients as well as the total number of the relapses without any effect with regard to distant metastases. Hypofractionated PORT is equally effective as conventional PORT (daily dose 2Gy, total dose 44Gy) with regard to locoregional control but has the clear logistical advantage. Purpose or Objective: Increasing the radiotherapy dose can result in improved local control for non-small-cell lung cancer (NSCLC) and can thereby improve survival. This can be compromised by accelerated repopulation of tumour cells during radiotherapy. Accelerated hypofractionated radiotherapy (AHRT) can expose tumors to a high dose of radiation in a short period of time. We have employed this approach in two groups of NSCLC: 1) early stage NSCLC patients who cannot tolerate the SABR treatment process (for example, extended periods in the treatment position) or who cannot travel to a centre with SABR; and 2) stage III NSCLC unfit for concurrent chemotheraphy. This study was performed to evaluate the feasibility of utilizing AHRT for these patients.
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Material and Methods: 76 patients (46 stage I-II and 30 local advanced NSCLC) were included. All patients had FDG-PET scan. Only the primary tumour and the positive mediastinal areas on the pre-treatmement FDG-PET scan were irradiated. Mean age was 77.9 ± 7.9 years. The performance status (PS) was > 2 in 50% of cases. The radiotherapy was delivered in 2.75 Gy fractions, once daily to a total dose of 66 Gy (BED10: 84 Gy). Sequential chemotheraphy (mainly platinum and vinorelbine) was administered in 95% of stage III patients. Acute/late toxicity was evaluated using the RTOG criteria.
Results: After a mean follow-up of 2 years, the median overall survival (OS) and cause specific survival (CSS) were 23 and 54 months, respectively. On multivariate Cox regression analysis, PS >2 was an independent risk factor for OS (p<0.0001) and CSS (p<0.0001). The major acute adverse reactions were grade 2 dermitis (18%), grade 2 esophagitis (10%) and grade 1 pneumonitis (26%). There were 34 patients with grade 1 late pneumonitis.
________________________________________________________________________________
Conclusion: AHRT is a reasonable alternative to conventional fractionated radiotherapy in stage I-II NSCLC without access to SABR and in stage III patients unfit for concurrent chemotheraphy. In both groups, treatment was well tolerated without grade 3 or higher treatment-related toxicity. PS >2 was an independent risk factor for OS and CSS. Purpose or Objective: Since 2014, the VERO system equipped with dynamic tracking DT has been used in our center for lung SBRT.The purpose of this work is to compare 2 compensation techniques for lung SBRT, DT and a method based on the definition of an ITV, in terms of PTV volume reduction and treatment time.
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Material and Methods:
The VERO is an O ring system equipped with a gimbaled linac allowing pan and tilt rotations and with a stereoscopic dual-source kV X-ray imaging allowing the guidance of the tracking. A 4DCT is done to measure the range of the target movements with the breath: if the amplitude is < 7mm, an ITV is determined on the MIP images and if it is > 7mm, the DT method is preferred. A gold marker (Visicoil, IBA) is then implanted in the lesion and a new 4DCT is realized 1 week later. The GTVDT is drawn on the exhale phase and the PTVDT is defined with a 5mm margin. The dose is prescribed on the isodose covering 95 % of the PTV (Monte Carlo): the peripheral tumors receive 3x17 Gy, near the thoracic wall 4x12 Gy and near the mediastin 8x7,5 Gy. The metastatic diseases received 5x10 Gy. For DT, treatments are delivered with 6-8 no coplanar beams.
Results: 77 patients were treated with lung SBRT, including 22 patients treated with DT. Among these 22 patients, the PTVITV was however estimated: the average size of the PTVDT was 28.8cc(6.5 -14.3 cc) and that of the PTVITV was 46.4cc(10.4 in 139 cc), so a 40 % reduction of the PTV volume. The average session length in DT was 35 min, the same as with the ITV method. The breathing rate of the patients was often irregular during the session and especially compared with the reference 4DCT. It did not affect the treatment delivery neither the guidance of the tracking. The clinical tolerance during and after the SBRT with tracking was excellent: 1 patient that was already treated for interstitial pulmonary fibrosis developed symptomatic radiation pneumonitis (RP). 5 other patients had radiological RP on the CT done during their first 6 months follow up period ; all of them received corticosteroid therapy and did not show any symptoms. There was no chest wall toxicity. Over a 16 months follow-up,1 patient did not benefit from treatment with DT SBRT and had a progressive disease.
Conclusion:
With a 40% reduction of the PTV, this DT technique makes it easy to monitor all the patients breathing motion, including very irregular rates, in a treatment time equivalent to more classical techniques based on the ITV.
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